UPDATE: UBS Upgrades Quest Diagnostics (DGX) to Buy

May 4, 2021 4:10 AM EDT
Get Alerts DGX Hot Sheet
Price: $127.50 -0.46%

Rating Summary:
    16 Buy, 13 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 15 | Down: 13 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - May 4, 2021 4:20 AM EDT)

UBS analyst Kevin Caliendo upgraded Quest Diagnostics (NYSE: DGX) from Neutral to Buy with a price target of $158.00 (from $135.00).

The analyst comments "We are upgrading shares of DGX to Buy from Neutral as we think Consensus underestimates the top-line potential for the base business beyond COVID (our 2022E/2023E revenue/EPS sits 2%/10% above Consensus, with Consensus implying LSD top-line growth in 2023E). Post-COVID, we think DGX top line growth is poised to accelerate to the MSDs (vs. a 1.5% avg. in the five years prior), which in our view supports multiple expansion. We believe underlying industry fundamentals are as healthy as they have been in 15 years with a stable outpatient reimbursement backdrop. We think any incremental PAMA pressure beyond 2022 would be manageable. Post COVID, DGX's balance sheet is only 1.7x levered, and the competitive backdrop suggests sustained momentum in Market Access Penetration, PLS, and M&A."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $132.71 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Hot Upgrades, Upgrades

Related Entities

UBS